First-line treatment with Keytruda (pembrolizumab) continues to promote significant survival benefits and durable responses in people with metastatic non-small cell lung cancer (NSCLC) and high levels of PD-L1, compared with standard chemotherapy, according to five-year data from the KEYNOTE-024 Phase 3 clinical trial. The results showed that twice as many Keytruda-treated patients were alive at five years, and that these individuals lived two times longer than those on chemotherapy. Keytruda is currently approved as a first-line treatment…
You must be logged in to read/download the full post.
The post First-line Keytruda Doubles 5-Year Survival in Certain Lung Cancer Patients, Data Show appeared first on BioNewsFeeds.